Blood pressure development in SHR and WKY rats: effects of neonatal monosodium glutamate treatment and evidence for transient hypertension in WKY rats

Metabolites and Hypertension: Insights into Hypertension as a Metabolic Disorder: 2019 Harriet Dustan Award

For over 100 years, essential hypertension has been researched from different perspectives ranging from genetics, physiology, and immunology to more recent ones encompassing microbiology (microbiota) as a previously underappreciated field of study contributing to the cause of hypertension. Each field of study in isolation has uniquely contributed to a variety of underlying mechanisms of blood pressure regulation. Even so, clinical management of essential hypertension has remained somewhat static. We, therefore, asked if there are any converging lines of evidence from these individual fields that could be amenable for a better clinical prognosis. Accordingly, here we present converging evidence which support the view that metabolic dysfunction underlies essential hypertension.

The Neonatal Treatment of Rats with Monosodium Glutamate Induces Morphological Changes in the Subfornical Organ

The parenteral administration of monosodium glutamate (MSG) to neonatal rats induces specific lesions in the central nervous system that lead to a well characterized neuroendocrinological dysfunction. Additionally, it has been shown that MSG-treated rats present a blunted blood pressure response to the injection of nitric oxide synthase inhibitors. Recently, a similar cardiovascular alteration has been reported after the electrolytic lesion of the anteroventral region of the third ventricle affecting the connections of the subfornical organ (SFO). We hypothesized that the treatment of neonatal rats with MSG could affect the nitrergic cells of the SFO. In the present work, we have looked for alterations in the NADPH-diaphorase activity (a commonly used marker for nitrergic neurons) in the SFO of MSG-treated rats of either sex and at two different ages. Our results shown that the treatment of neonatal rats with MSG induced a substantial reduction in the volume of the SFO and in the number of its nitrergic cells with regard to control animals. These findings suggest that the SFO could be implicated in some of the cardiovascular alterations observed in MSG-treated rats.

Visual dysfunction in the spontaneously hypertensive rat

We report two forms of visual defect in the spontaneously hypertensive rat (SHR) compared to its normotensive control strain (WKY). Ten-month-old male SHR and WKY were tested for intensity discrimination ability using a Y-maze and food reward. The SHR took more trials in the acquisition phase of the task using white light. In the test phase, in which the white light intensity difference was reduced, there was no significant difference in performance between SHR and WKY. Also, there was no significant difference between the strains when red light was used. The defect in SHR occurred in the blue range of the spectrum. Using blue light, the performance of SHR declined significantly at an intensity difference of 1.15 lux, whereas the performance of WKY did not decline significantly until the difference reached 0.01 lux. The defect in SHR for intensity discrimination was not related to cataract formation, but we detected a strain difference in the nuclei of the photoreceptor cells. Thus, this visual dysfunction may involve the rod photoreceptors. Further testing revealed a deficit in visual acuity in SHR aged 40-66 days, prior to the development of hypertension. Thus, the visual dysfunction of SHR is not secondary to their development of hypertension, but rather a discrete characteristic of the strain.